Inosine pranobex

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Inosine pranobex
Accession Number
DB13156
Type
Small Molecule
Groups
Approved
Description

Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

Structure
Thumb
Synonyms
  • IAD
  • Inosine acedobene dimepranol
  • Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
  • Inosiplex
  • Isoprinosine
  • Methisoprinol
External IDs
NP-113 / NPT-10381
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImunovirTabletOralKora Healthcare2000-01-25Not applicableCanada
IsoprinosineTabletOralNewport Pharmaceuticals International1997-06-052000-02-04Canada
Isoprinosine Tab 500mgTabletOralSystemed Inc.1993-12-311996-09-10Canada
Isoprinosine Tab 500mgTabletOralNewport Pharms International Inc.1983-12-311996-09-10Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
W1SO0V223F
CAS number
36703-88-5
Weight
Average: 1115.249
Monoisotopic: 1114.554641092
Chemical Formula
C52H78N10O17
InChI Key
YLDCUKJMEKGGFI-KSIULYHRSA-N
InChI
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1
IUPAC Name
tris((2R)-1-(dimethylamino)propan-2-ol); tris(4-acetamidobenzoic acid); 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
SMILES
C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O

Pharmacology

Indication

Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.

Associated Conditions
Pharmacodynamics

Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.

Mechanism of action

Inosine pranobex stimulates cell-mediated immune processes to viral infections.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Rapidly absorbed from GIT

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Via urine

Half life

50 min

Clearance
Not Available
Toxicity

Mouse LD50 (Intravenous ): 1570 mg/kg Muse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. ChemIDplus [Link]
  3. Pubchem [Link]
External Links
KEGG Drug
D01995
PubChem Compound
131704326
PubChem Substance
347829266
ChemSpider
58829622
Wikipedia
Inosine_pranobex
ATC Codes
J05AX05 — Inosine pranobex
AHFS Codes
  • 08:18.00 — Antivirals
  • 08:18.92 — Miscellaneous Antivirals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphatic Diseases3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-2.5ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)8.93ChemAxon
pKa (Strongest Basic)0.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area129.2 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity61.33 m3·mol-1ChemAxon
Polarizability24.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Benzoic acids / Benzoyl derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans
show 14 more
Substituents
Purine nucleoside / Glycosyl compound / N-glycosyl compound / 6-oxopurine / Pentose monosaccharide / Purinone / Hypoxanthine / Imidazopyrimidine / Benzoic acid or derivatives / Purine
show 38 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on December 03, 2016 17:28 / Updated on November 20, 2019 12:33